CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

After BriaCell Treatment Image B: Swelling (induration) around the metastasis (lower arrow) demonstrates the liver metastasis ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...

A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...

Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Gen Cytotoxic Therapeutic Leveraging the ELANE ...